Healthcare
TerrAscend Corp.(TSNDF)
Live Price
Offline$0.69
+5.99% today
1Y Change
+180.49%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $230.00M
- Revenue Growth
- -40.9%
- EPS Growth
- -3.6%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
TerrAscend Corp. (TSNDF) is a Healthcare stock with a market cap of $230.00M and listed on OTC. The stock last traded around $0.69 and up 180.5% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of -40.9%, EPS growth of -3.6%, a dividend yield of 0.0%. What stands out right now is revenue -40.9%, EPS -3.6%, free cash flow -53.4% with operating margin 15.4% and ROIC -186.0%. Valuation is more restrained than many high-expectation growth names at price/sales 0.9. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TSNDF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-40.9% vs +7.6% peer median
Operating Margin
Below sector median
+15.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -40.9% and EPS is at -3.6%, with operating margin around 15.4%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.7% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -7.9% | -2.7% | +1.0% |
2026 Mar 12, 2026 | +150.0% | +4.1% | +4.9% | -4.7% |
2025 Nov 6, 2025 | -100.0% | +13.6% | +5.8% | -8.5% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TSNDF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TSNDF Max Drawdown
-66.96%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TSNDF and SPY.
Company Overview
TerrAscend Corp.
Other OTC
TerrAscend Corp. cultivates, produces, and sells cannabis products in Canada and the United States. The company manufactures vaporizables, concentrates, topicals, flowers, tinctures, and edibles. It offers its products under the brand name Kind Tree Cannabis, GAGE Cannabis, Legend, Valhalla Confections, State Flower Cannabis, Ilera Healthcare, Wana, Cookies, and Lemonnade. The company also operates retail dispensaries under the Apothecarium, TerrAscend, Pinnacle Emporium, GAGE Cannabis, and State Flower brand names. It serves medical patients and adult-use consumers in North America. The company was incorporated in 2017 and is headquartered in King Of Prussia, Pennsylvania.
- Leadership
- Ziad Ghanem
- IPO Date
- Nov 17, 2017
- Employees
- 950
- Street Address
- 357 South Gulph Road
- Mailing
- King of Prussia, PA, 19406
- Region
- King of Prussia, PA, US
- Reporting Currency
- USD
- Investor Line
- 1 855 837 7295
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 8.4
- Price/Sales
- 0.9
- Price/Book
- 2.4
Growth
- Revenue
- -40.9%
- EPS
- -3.6%
- Free Cash Flow
- -53.4%
Profitability
- Gross Margin
- 51.3%
- Operating Margin
- 15.4%
- Net Margin
- -32.1%
- ROE
- -72.8%
- ROIC
- -186.0%
Balance Sheet
- Debt/Equity
- 2.64
- Current Ratio
- 1.38
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.